Minimal Residual Disease (MRD)

The persistence of cancerous cells after treatment, known as minimal (or measurable) residual disease, may lead to relapse.

Detecting MRD: Methods and Sensitivity6,7

Diagnostic test
Sensitivity
Methods and Sensitivity Diagnostics test: 'flow cytometry' icon
Flow cytometryA rapid and qualitative method of identifying cancer cells
  • 1 cancer cell in 10,000 normal cells
Methods and Sensitivity Diagnostics test: 'Polymerase chain reaction' icon
Polymerase chain reactionA well-established method in which a specific section of DNA from cancer cells is replicated and amplified
  • 1 cancer cell in 100,000 normal cells
Methods and Sensitivity Diagnostics test: 'Next-generation sequencing' icon
Next-generation sequencingAn extremely sensitive DNA sequencing method
  • 1 cancer cell in 1,000,000 normal cells

Where is your nearest MRD testing facility?

The link below is an informational resource to help healthcare providers locate MRD testing facilities for clinically appropriate patients. Amgen does not refer, recommend, or endorse healthcare providers or facilities listed here. The selection of a healthcare provider is a patient's choice and should be carefully considered. Please contact facilities directly to learn more about the availability of MRD testing at these locations.

DOWNLOAD THE LIST ->
LEARN MORE ABOUT:

MRD in acute lymphoblastic leukemia ->

For more information on MRD, play our interactive game and download the resources below

References: 1. Jain N, et al. In: Hoffman R, et al, eds. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA: Saunders-Elsevier; 2013:960-980. 2. Gökbuget N, et al. Blood. 2012;120:1868-1876. 3. Pettit K, et al. Leuk Lymphoma. 2016;57:1527-1533. 4. Berry DA, et al. JAMA Oncol. 2017;3:e170580. 5. Harousseau J-L, et al. J Clin Oncol. 2017;35:2863-2865. 6. Campana D. Semin Hematol. 2009;46:100-106. 7. Ladetto M, et al. Leukemia. 2014;28:1299-1307.